Literature DB >> 12418587

Short-term variability of exhaled nitric oxide in young male patients with mild asthma and in healthy subjects.

H Ekroos1, J Karjalainen, S Sarna, L A Laitinen, A R A Sovijärvi.   

Abstract

BACKGROUND: Exhaled nitric oxide (NOexp) is an indicator of eosinophilic airways inflammation. This study evaluated short-term variability of NOexp in 13 healthy subjects (19-41 years, eight males) and in 31 patients with asthmatic respiratory symptoms (19-21 years, all male) to obtain data for assessment of short-term changes of NOexp in clinical situations.
METHODS: Mild asthma was confirmed in 10 patients (Group = asthma). Twenty-one patients with asthmatic respiratory symptoms did not fulfill the functional criteria of asthma (Group = respiratory symptoms). The procedure to determine NOexp followed the European Respiratory Society (ERS) guidelines; the mean expiratory flow used during sampling was 0.09-0.12 l/s. NOexp for each subject was determined as the mean of at least three successive measurements at the baseline, followed by determinations at 10 min, 6 h and 24 h after the baseline.
RESULTS: At the baseline, the mean (SD) value of NOexp was 6.6 (2.3) parts per billion (ppb) in the healthy controls, and significantly higher both in patients with respiratory symptoms (14.6 (11) ppb, P = 0.0076) and in those with asthma (34.2 (43) ppb, P < 0.001). Intraclass correlation coefficient of NOexp measured at baseline and after an interval of 10 min was 0.959 in healthy subjects, 0.986 in patients with respiratory symptoms and 0.936 in asthma patients, respectively. Short-term variability in terms of coefficient of variation (CoV) of repeated measurements of NOexp at 10 min, 6 hand 24 h was 5.1, 10.8 and 11.7% in healthy subjects, 71, 16.4 and 22.2% in patients with respiratory symptoms and 13.5, 19.4 and 26.4% in asthma patients, respectively.
CONCLUSIONS: Reproducibility of NOexp using standardized methods was good both in healthy subjects and in asthmatic patients. However, in asthmatics the short-term variation of NOexp was over two times as high as in healthy subjects. The level of NOexp was elevated, except in asthma, also in patients with asthmatic respiratory symptoms who did not fulfill the functional criteria of asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12418587     DOI: 10.1053/rmed.2002.1378

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

1.  Variability of FeNO in healthy subjects at 2240 meters above sea level.

Authors:  Laura Gochicoa-Rangel; Fermín Rojas-Cisneros; José Luis Miguel-Reyes; Selene Guerrero-Zúñiga; Uri Mora-Romero; Ana Karen Maldonado-Mortera; Luis Torre-Bouscoulet
Journal:  J Clin Monit Comput       Date:  2015-07-15       Impact factor: 2.502

2.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

Review 3.  Asthma outcomes: biomarkers.

Authors:  Stanley J Szefler; Sally Wenzel; Robert Brown; Serpil C Erzurum; John V Fahy; Robert G Hamilton; John F Hunt; Hirohito Kita; Andrew H Liu; Reynold A Panettieri; Robert P Schleimer; Michael Minnicozzi
Journal:  J Allergy Clin Immunol       Date:  2012-03       Impact factor: 10.793

Review 4.  Exhaled nitric oxide measurements: clinical application and interpretation.

Authors:  D R Taylor; M W Pijnenburg; A D Smith; J C De Jongste
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

5.  Repeatability of exhaled nitric oxide measurements in patients with COPD.

Authors:  Annamari Rouhos; Annette Kainu; Päivi Piirilä; Seppo Sarna; Ari Lindqvist; Jouko Karjalainen; Anssi R A Sovijärvi
Journal:  Clin Physiol Funct Imaging       Date:  2010-09-23       Impact factor: 2.273

6.  Atopic sensitization to common allergens without symptoms or signs of airway disorders does not increase exhaled nitric oxide.

Authors:  Annamari Rouhos; Annette Kainu; Jouko Karjalainen; Ari Lindqvist; Päivi Piirilä; Seppo Sarna; Tari Haahtela; Anssi R A Sovijärvi
Journal:  Clin Respir J       Date:  2008-07       Impact factor: 2.570

Review 7.  Clinical application of exhaled nitric oxide measurements in a korean population.

Authors:  Woo-Jung Song; Ji-Won Kwon; Eun-Jin Kim; Sang-Min Lee; Sae-Hoon Kim; So-Yeon Lee; Sang-Heon Kim; Heung-Woo Park; Yoon-Seok Chang; Woo Kyung Kim; Jung Yeon Shim; Ju-Hee Seo; Byoung-Ju Kim; Hyo Bin Kim; Dae Jin Song; Gwang Cheon Jang; An-Soo Jang; Jung-Won Park; Ho-Joo Yoon; Joo-Shil Lee; Sang-Heon Cho; Soo-Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2014-08-19       Impact factor: 5.764

8.  Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.

Authors:  P E Silkoff; M Laviolette; D Singh; J M FitzGerald; S Kelsen; V Backer; C Porsbjerg; P O Girodet; P Berger; J N Kline; S Khatri; P Chanez; V S Susulic; E S Barnathan; F Baribaud; M J Loza
Journal:  Respir Res       Date:  2016-04-23

9.  Reproducibility of exhaled nitric oxide in smokers and non-smokers: relevance for longitudinal studies.

Authors:  Abraham Bohadana; Jean-Pierre Michaely; Dan Teculescu; Pascal Wild
Journal:  BMC Pulm Med       Date:  2008-02-28       Impact factor: 3.317

10.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.